A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
P-tau235: a novel biomarker for staging preclinical Alzheimer's disease
Tekijät: Lantero-Rodriguez Juan, Snellman Anniina, Benedet Andrea L, Milà-Alomà Marta, Camporesi Elena, Montoliu-Gaya Laia, Ashton Nicholas J, Vrillon Agathe, Karikari Thomas K, Gispert Juan Domingo, Salvadó Gemma, Shekari Mahnaz, Toomey Christina E, Lashley Tammaryn L, Zetterberg Henrik, Suárez-Calvet Marc, Brinkmalm Gunnar, Neto Pedro Rosa, Blennow Kaj
Kustantaja: WILEY
Julkaisuvuosi: 2021
Journal: EMBO Molecular Medicine
Tietokannassa oleva lehden nimi: EMBO MOLECULAR MEDICINE
Lehden akronyymi: EMBO MOL MED
Artikkelin numero: e15098
Vuosikerta: 13
Numero: 12
Sivujen määrä: 16
ISSN: 1757-4676
eISSN: 1757-4684
DOI: https://doi.org/10.15252/emmm.202115098
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/67998473
Alzheimer's disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p-tau) species such as p-tau217 and p-tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression during preclinical AD are still needed. Combining exploratory and targeted mass spectrometry methods in neuropathologically confirmed brain tissue, we observed that p-tau235 is a prominent feature of AD pathology. In addition, p-tau235 seemed to be preceded by p-tau231, in what appeared to be a sequential phosphorylation event. To exploit its biomarker potential in cerebrospinal fluid (CSF), we developed and validated a new p-tau235 Simoa assay. Using three clinical cohorts, we demonstrated that (i) CSF p-235 increases early in AD continuum, and (ii) changes in CSF p-tau235 and p-tau231 levels during preclinical AD are consistent with the sequential phosphorylation evidence in AD brain. In conclusion, CSF p-tau235 appears to be not only a highly specific biomarker of AD but also a promising staging biomarker for the preclinical phase. Thus, it could prove useful tracking disease progression and help enriching clinical trial recruitment.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
